vimarsana.com

Page 3 - பிரிவு ஆஃப் பெண்ணோயியல் புற்றுநோயியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer

Share: U.S. FDA Granted Fast Track Designation in 2018 Trial Expected to Enroll 300-400 Patients at Approximately 165 Sites in the U.S. and Europe in Simplified Adaptive Trial Design Conference Call and Webcast Today at 8:30 a.m. ET HOUSTON, April 27, 2021 (GLOBE NEWSWIRE) Aravive Inc. (NASDAQ:ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced the Company has dosed the first patient in its Phase 3 trial of AVB-500 in platinum resistant ovarian cancer (PROC). The trial is evaluating the efficacy of AVB-500 in combination with paclitaxel (chemotherapy) and the primary endpoint is progression free survival.

Dana-Farber to present more than 30 research studies at American Association for Cancer Research Annual Meeting 2021

Session Time: April 13, 11:17-11:39 a.m. EST Summary: Kaelin will highlight the important physiologic constraints a cancer tissue must operate within, focusing on the critical role hypoxia plays in not only tumor growth but progression, and how modulating the hypoxia machinery will limit tumor progression. The ability to target cancer at several molecular levels provides hope that our therapies will not only be more effective but also more durable. The lingering question is how to deploy these approaches by identifying which patients are most likely to benefit. In addition to the exciting research presentations, Andrew Aguirre, MD, PhD, of the Dana-Farber Center for Gastrointestinal Oncology, has been named a 2021 AACR NextGen Star. Aguirre will present during the NextGen Stars Spotlight Session: Genetics and Epigenetics.

Nine-person board to conduct search for Barry Alvarez’s replacement

By Logan Rude MADISON, Wis. The search for a Barry Alvarez’s replacement has begun. Alvarez announced announced his retirement Tuesday after more than 30 years with the university. He spent 17 of those years as athletic director. Now, a nine-member committee, chaired by UW Athletic Board Chair Peter Miller, will conduct the search for Alvarez’s replacement. “We look forward to a robust and extensive search to identify the best candidate to lead the UW Athletic Department forward,” Miller said. University officials said a new director of athletics could be hired by this summer. UW-Madison Chancellor Rebecca Blank said Alvarez’s replacement “should be able to continue his legacy of success and make our alumni and fans across the state proud.”

Nine-person board to conduct search for Barry Alvarez s replacement

MADISON, Wis. The search for a Barry Alvarez’s replacement has begun. Alvarez announced announced his retirement Tuesday after more than 30 years with the university. He spent 17 of those years as athletic director. Now, a nine-member committee, chaired by UW Athletic Board Chair Peter Miller, will conduct the search for Alvarez’s replacement. “We look forward to a robust and extensive search to identify the best candidate to lead the UW Athletic Department forward,” Miller said. University officials said a new director of athletics could be hired by this summer. UW-Madison Chancellor Rebecca Blank said Alvarez’s replacement “should be able to continue his legacy of success and make our alumni and fans across the state proud.”

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.